Compandia Announces Name Change and New Diagnostic Concept

NOTTINGHAM, England, September 15, 2010 - Compandia has announced a name change to CompanDX. The company
is a biomarker discovery company providing services to the Pharma and Biotech
sectors but increasingly, as a result of in-house R&D, is identifying
biomarkers that may lead to new diagnostic services and products of its own.
Andy Sutton CEO of CompanDX explained "we have grown the service side of the
business over the last 9 months and are delivering biomarker discovery
services to large pharma, small biotech and diagnostic companies. We and our
investors have always recognised the significant upside potential in the
research work we conduct with collaborators and in the laboratories of our
founders, the new name reflects this activity as we start to build our IP
portfolio around the signatures and biomarker panels we are developing."

CompanDX also announced the launch of its new "Time to an
Event" breast cancer gene panel. CompanDX presents a plenary session today at
the British Breast Cancer meeting in Nottingham describing the use of its
Risk Distiller bioinformatics tools to deliver the first diagnostic that
predicts time to a clinical event. CompanDX scientists have used three public
datasets from different clinics to derive a 31 gene signature that predicts
time to metastasis following initial surgery and biopsy. The gene signature
was subsequently validated on a fourth dataset from yet another clinical
centre. Across these patient cohorts the actual versus signature predicted
time to metastases has a correlation of 0.86 (p< 0.0001). Furthermore
CompanDX for the first time has predicted a "prospective Kaplan Meier curve"
which accurately tracks the actual survival curve from the combined data.
Here median time to event in the patient population was 3.5 years, this was
predicted to be 3.7 years by the CompanDX gene signature with no significant
differences between the actual and the CompanDX curves (p = 0.555). Andy
Sutton commented "We are very excited about this study, firstly it is real
world data from different labs, with no abstraction of outlying patient data.
Furthermore it is a 'world first' of a totally new type of diagnostic
paradigm with potential to significantly alter clinical management."

CompanDX has applied funding to validate this in the clinic
and has secured collaboration with leading clinical centres in London,
Nottingham, Cardiff and Holland and also industry support from a world
leading diagnostics company in the development of the assay.

Contacts: Andy Sutton - +44(0)7764-580468 - andy.sutton at compandx.com .